$0.75
(Market cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.3
-
Debt to Equity
0
-
Book Value
$6.5
-
EPS
$-24.7
-
Face value
--
-
Shares outstanding
3,943,887
6 Years Aggregate
CFO
$-248.63 Mln
EBITDA
$-288.67 Mln
Net Profit
$-287.74 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Athira Pharma Inc (ATHA)
| 1.2 | 63.7 | 97.9 | 133.5 | -34.0 | -48.7 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Athira Pharma Inc (ATHA)
| 29.0 | -75.6 | -23.3 | -75.7 | -62.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Athira Pharma Inc (ATHA)
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis,... which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington. Read more
-
President, CEO & Director
Dr. Mark J. Litton M.B.A., Ph.D.
-
President, CEO & Director
Dr. Mark J. Litton M.B.A., Ph.D.
-
Headquarters
Bothell, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Athira Pharma Inc (ATHA)
What is the current share price of Athira Pharma Inc (ATHA) Today?
The share price of Athira Pharma Inc (ATHA) is $7.66 (NASDAQ) as of 13-Mar-2026 09:30 EDT. Athira Pharma Inc (ATHA) has given a return of -33.96% in the last 3 years.
What is the current PB & PE ratio of Athira Pharma Inc (ATHA)?
Since, TTM earnings of Athira Pharma Inc (ATHA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.31 |
1.16 |
2024 |
-0.02 |
0.05 |
2023 |
-0.08 |
0.07 |
2022 |
-0.13 |
0.05 |
2021 |
-0.89 |
0.15 |
What is the 52 Week High and Low of Athira Pharma Inc (ATHA)?
The 52-week high and low of Athira Pharma Inc (ATHA) are Rs 8.36 and Rs 2.20 as of 31-Aug-2026.
What is the market cap of Athira Pharma Inc (ATHA)?
Athira Pharma Inc (ATHA) has a market capitalisation of $ 27 Mln as on 13-Mar-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Athira Pharma Inc (ATHA)?
Before investing in Athira Pharma Inc (ATHA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.